---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-001384"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:03:45.549694+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunic reports positive Phase 2 CALLIPER interim data: NfL reduced 22.4% vs placebo in PMS

## Summary
- Vidofludimus calcium lowered serum NfL by 22.4% vs placebo at 24 weeks in overall PMS (p=0.01 post hoc).
- Non-active SPMS subgroup showed 20.1% NfL reduction; PPMS showed 18.8% reduction.
- GFAP increased 3.7% for drug vs 4.4% for placebo at 24 weeks; 2.7% vs 6.4% at 48 weeks.
- Top-line CALLIPER data expected April 2025; Phase 3 ENSURE interim data late 2024.
- NfL reduction numerically higher than historical Ocrevus data in PPMS (22.4% vs 12.4%).

## SEC filing metadata
- accession: 0001193805-23-001384
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380523001384/0001193805-23-001384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380523001384/e618990_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-001384
- JSON: https://secwatch.observer/filing/0001193805-23-001384.json
- Plain text: https://secwatch.observer/filing/0001193805-23-001384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.